Bruce Booth, Director at Kymera Therapeutics, Inc. (KYMR), sold 398,765 shares at $99.98 ($44.0M) on 2026-06-23, disclosed to the SEC on 2026-06-25.
Scheduled sale ($44.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $99.98 | 1,235 | $123K | 0.3% |
| 2 | $99.98 | 173 | $17K | 0.0% |
| 3 | $100.42 | 103,688 | $10.4M | 23.7% |
| 4 | $100.42 | 14,513 | $1.5M | 3.3% |
| 5 | $101.14 | 14,490 | $1.5M | 3.3% |
| 6 | $101.14 | 2,029 |
| $205K |
| 0.5% |
| 7 | $107.30 | 1,399 | $150K | 0.3% |
| 8 | $107.30 | 9,994 | $1.1M | 2.4% |
| 9 | $108.02 | 159 | $17K | 0.0% |
| 10 | $108.02 | 23 | $2K | 0.0% |
| 11 | $108.83 | 14,351 | $1.6M | 3.6% |
| 12 | $108.83 | 2,011 | $219K | 0.5% |
| 13 | $110.30 | 265 | $29K | 0.1% |
| 14 | $110.30 | 1,915 | $211K | 0.5% |
| 15 | $110.79 | 86 | $10K | 0.0% |
| 16 | $110.79 | 614 | $68K | 0.2% |
| 17 | $111.89 | 100 | $11K | 0.0% |
| 18 | $111.89 | 719 | $80K | 0.2% |
| 19 | $113.70 | 1,437 | $163K | 0.4% |
| 20 | $113.70 | 10,215 | $1.2M | 2.6% |
| 21 | $114.65 | 1,289 | $148K | 0.3% |
| 22 | $114.65 | 9,229 | $1.1M | 2.4% |
| 23 | $115.57 | 8,389 | $970K | 2.2% |
| 24 | $115.57 | 58,205 | $6.7M | 15.3% |
| 25 | $116.53 | 11,375 | $1.3M | 3.0% |
| 26 | $116.53 | 81,500 | $9.5M | 21.6% |
| 27 | $117.50 | 24,268 | $2.9M | 6.5% |
| 28 | $117.50 | 3,359 | $395K | 0.9% |
| 29 | $118.60 | 2,646 | $314K | 0.7% |
| 30 | $118.60 | 19,089 | $2.3M | 5.1% |
| Total | $110.31 avg | 398,765 | $44.0M | 100% |
| Filing → |
| KYMR | SELL | 2026-06-30 | $3.4M | — | Filing → |
| KYMR | SELL | 2026-06-25 | $34.8M | — | Filing → |
| KYMR | SELL | 2026-06-22 | $45.3M | — | Filing → |